Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report. A Johnson & Johnson spokesperson said ...
One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable safety and immunogenicity outcomes.
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results